Diagnostic and Interventional Cardiology

MedWatch, The FDA Safety Information and Adverse Event Reporting Program, announced that Pfizer is recalling Accuretic (quinapril hydrochloride/hydrochlorothiazide) tablets distributed by Pfizer as well as two authorized generics distributed by Greenstone (quinapril HCL and hydrochlorothiazide and quinapril HCl/hydrochlorothiazide) due to the presence of a nitrosamine, N-nitroso-quinapril, above the Acceptable Daily Intake level.

Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Top 10: Most Read Cardiology Content in March 2022

Here is what you and your colleagues found to be most interesting in the field of cardiology during the month of March ...

March 31, 2022

News | Heart Failure

Bone Marrow Contributes to the Development of Atherosclerosis

April 1, 2022 – The activation of the bone marrow appears to play a key role in the origin and development of ...

March 31, 2022

Stereotaxis’ Genesis Robotic Magnetic Navigation (RMN) system

News | Robotic Systems

National Institute of Cardiology Becomes First Hospital in Poland to Establish Advanced Robotic Program to Treat Heart Rhythm Disorders

April 1, 2022 – Stereotaxis, the global leader in innovative robotic technologies for the treatment of cardiac ...

March 31, 2022

Sponsored Content

ASCEND provides the tools that not only address the unique needs of each cardiovascular subspecialty and to care for patients from infancy into their golden years, they also innovates next-generation solutions and services that empower the provider community to truly transform their cardiovascular services

Feature | Information Technology

SPONSORED CONTENT: Unveiling the Future of Cardiovascular Workflow

Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...

March 21, 2024

The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held April 3-5 at the Bella Center in Copenhagen, Denmark and online. Explore the scientific program.

News | ESC

EHRA 2022: Cutting Edge Science in Heart Rhythm Disorders

March 31, 2022 — The annual congress of the European Heart Rhythm Association (EHRA), a branch of the ESC, will be held ...

March 31, 2022

News | Coronavirus (COVID-19)

International Multi-center Study Confirms Stroke Risk in Younger Healthier COVID-19 Patients

April 1, 2022 – Over the course of the pandemic, a number of studies examined whether COVID-19 patients were at ...

March 31, 2022

News | Population Health

Living Near Green Areas Reduces the Risk of Suffering a Stroke by 16%

April 1, 2022 – The risk of suffering an ischemic stroke, the most common type of cerebrovascular event, is 16% less in ...

March 31, 2022

Sponsored Content

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability to diagnose cardiac disease with greater accuracy and precision

Feature | Cardiac Imaging

SPONSORED CONTENT: Finding the Right Solution

Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...

March 05, 2024

Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it easier to predict if a person will have a heart attack.

News | CT Angiography (CTA)

Artificial Intelligence Tool May Help Predict Heart Attacks

March 31, 2022 – Investigators from Cedars-Sinai have created an artificial intelligence-enabled tool that may make it ...

March 31, 2022

DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software, announced today a multi-year agreement with Change Healthcare, a global industry-leading provider of enterprise imaging solutions.

News | Cardiovascular Ultrasound

DiA Imaging Analysis Teams up with Healthcare Technology Company to Expand its AI Offering for Echo-lab Cardiac Exams

March 31, 2022 – DiA Imaging Analysis Ltd, a leading global provider of AI-powered ultrasound analysis software ...

March 31, 2022

Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has successfully completed enrollment in its phase 2 study of istaroxime in early cardiogenic shock caused by heart failure.

News | Pharmaceuticals

Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock

March 31, 2022 – Windtree Therapeutics, a biotechnology company focused on advancing multiple late-stage interventions ...

March 31, 2022

Sponsored Content

Blog

BLOG: Combining Local Impedance with Contact Force to Perform RF Ablation

When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...

December 11, 2023

Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results from the first-in-human clinical trial of Embrace Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR).

News | Embolization devices

Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients

March 31, 2022 – Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral ...

March 31, 2022

Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the first patient was treated in a U.S. early feasibility study evaluating PerQseal+, the next generation of the company’s PerQseal device.

News | Structural Heart

Vivasure Medical Announces First Patient Treated in U.S. Early Feasibility Study Evaluating PerQseal+

March 31, 2022 – Vivasure Medical, a company pioneering novel fully absorbable technology for percutaneous vessel ...

March 31, 2022

One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an important genetic risk factor for premature heart disease and stroke.

News | Heart Failure

The Silent, Undetected Cause of Early Heart Disease

March 31, 2022 – One in 5 people worldwide have high Lipoprotein(a) – sometimes referred to as “L-P-little a” – an ...

March 31, 2022

Sponsored Content

Case Study | Hemodynamic Monitoring Systems

TECH BRIEF — Integrated Hemodynamic Monitoring System Helps Improve Lab Performance, Efficiency

Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...

November 14, 2023

University Hospitals Cleveland Medical Center

News | Population Health

Study Shows Link Between Socioeconomic Deprivation and Premature Cardiovascular Mortality

March 31, 2022 – People living in socially-deprived areas of the United States are more likely to die prematurely from ...

March 31, 2022

A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate infection by SARS-CoV-2 can cause an imbalance in the cardiovascular system of young adults without pre-existing diseases.

News | Coronavirus (COVID-19)

Study: Even Mild or Moderate COVID-19 Can Affect the Cardiovascular System in Young Adults

March 31, 2022 – A study conducted at São Paulo State University (UNESP) in Brazil shows that even mild to moderate ...

March 31, 2022

Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that, for the first time, distinguishes between treatable sudden cardiac arrest and untreatable forms of the condition.

News | Sudden Cardiac Arrest

Cedars-Sinai Researchers Are the First to Distinguish Between Treatable and Untreatable Sudden Cardiac Arrest

March 30, 2022 — Clinician-scientists in the Smidt Heart Institute at Cedars-Sinai developed a clinical algorithm that ...

March 30, 2022